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Abstract 
Obesity, a chronic disease, is a global epidemic that affects millions of lives and 
increases the risk of several comorbidities such as Type 2 diabetes, musculoskeletal 
disorders, cardiovascular disease, and cancer. Obesity is the leading cause of death 
globally, and is associated with an excessive accumulation of white adipose tissue 
(WAT). Although obesity is a serious condition, safe, long-term drug therapies are 
limited. A second type of adipose tissue is known as brown adipose tissue (BAT), which 
functions as an energy dissipater in the form of heat, as opposed to energy storing WAT. 
Previous research has shown that the mitochondrial uncoupling protein 1 (UCP1), 
activates the thermogenic properties of BAT [1]. WAT lacks the expression of UCP1 and 
therefore has no protective mechanisms against obesity and stores energy in the form of 
triglycerides. Thermogenic BAT has been identified in adult humans [2], as such, this 
discovery has been an attractive target for anti-obesity therapy. Recently, studies have 
suggested that WAT can be transdifferentiated into brown-like beige adipose tissue 
(BeAT). This transdifferentiation process is referred to as “beiging” and is mediated by 
the activation of the sympathetic nervous system. Activation of BeAT, similar to BAT, 
generates heat at the expense of ATP. Additionally, immune cells like macrophages play 
an important role in the induction of thermogenesis in WAT and contribute to the beiging 
of WAT [3]. 
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Current treatments for obesity, as well as “browning” agents, propose their own 
risks to humans and are not ideal long-term solutions for anti-obesity therapy. 
Consequently, many phytochemicals have been explored for their safe anti-obesity 
affects and as browning agents. Recently, xanthohumol (XN), a prenylated flavonoid 
found in Hops flowers, has been reported to inhibit adipogenesis and stimulate the 
apoptosis of adipocytes [4]. However, there are no published studies demonstrating the 
effects of XN on thermogenesis. In this current study, we will explore novel anti-obesity 
effects of XN to propose a multi-faceted approach for prevention and treatment of 
obesity. We propose to investigate the direct and indirect effects of XN on the induction 
of beiging in white adipocytes. Furthermore, we will investigate the role of adenosine 
monophosphate activated kinase (AMPK) signaling pathway in the induction of beiging.  
The in vitro cell culture models utilized in this study are murine adipocyte (3T3-
L1) and macrophage (RAW264.7) cell lines. Cell viability assay, Western blotting, 
ELISA, MitoTracker Green™, Oil Red O staining, AdipoRed™ assay, and a Transwell co-
culturing system are employed to demonstrate the effects of XN on beiging and the role 
of AMPK pathway in XN-induced beiging. Our data suggests that XN has the ability to 
directly induce transdifferentiation of white to beige adipocytes and indirectly induce 
beiging by activating anti-inflammatory M2 macrophages. Furthermore, data also 
indicates a role of the AMPK pathway in XN-mediated anti-obesity effects. 
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1.1 Epidemiology of Obesity 
 The prevalence of obesity has doubled since 1980 and in 2014, approximately 
13% of the population 18 years and older globally were considered obese [5]. It has been 
projected that by 2030, 51.1% of the United States adult population will be obese [6]. 
Obesity is a chronic disease that causes and exacerbates other co-morbid diseases [7] and 
is the leading cause of mortality in the U.S. and worldwide [8]. These comorbidities 
include cardiovascular diseases, insulin resistance, gallbladder disease, musculoskeletal 
disorders, asthma, malignancies, mental health illnesses, and a decrease in the quality of 
life of an obese person [8]. Though preventable, obesity poses a major threat to the health 
of billions of lives worldwide.  
 The Body Mass Index (BMI) is an indirect measurement of a person’s body fat, 
based on their weight and height, and assesses obesity in adults. In adults, a BMI greater 
than 30 indicates obesity. A BMI of 40 and greater indicates morbid obesity. At the 
forefront of concern, obesity is not limited to adults. In 2014, 41 million children, 
younger than 5 years old, were overweight or obese [5].  
 The etiology of obesity is complex and cannot be contributed to a single factor. 
Some factors that have been attributed to obesity include the adaptation of a sedimentary 
lifestyle, an increase in readily available calorie-dense foods, genetic predispositions, 
existing hormonal conditions, medications, and socioeconomic status  [9]. This makes 
obesity difficult to treat and prevent.  
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1.2 The Morphology and Physiology of Adipose Tissue 
Adipose tissue functions as a metabolic and endocrine organ responsible for 
maintaining systemic energy homeostasis as well as the production and secretion of 
various adipokines. These adipokines act to regulate food intake, energy metabolism, and 
inflammatory responses influencing the brain, muscle, liver, and other vascular tissues 
via autocrine, endocrine, and paracrine pathways [10]. Energy homeostasis is achieved 
when energy intake in the form of food, is equal to the amount of energy expenditure. 
Whenever energy intake exceeds energy expenditure, that excess energy is stored in the 
form of triglycerides in adipocytes which can eventually lead to obesity. Weight loss 
occurs when energy intake is significantly lower than the amount of energy expenditure. 
There are two types of obesity: hyperplasic, characterized by an increased number of 
adipocytes, and hypertrophic, characterized by an increase in the size of adipocytes. 
Adipose tissue is a heterogeneous, areolar connective tissue consisting of preadipocytes, 
adipocytes, multipotent stem cells, and immune cells such as macrophages [11].   
1.2.1 Adipogenesis 
Preadipocytes can be differentiated into mature adipocytes and mature adipocytes 
can be de-differentiated into preadipocytes, only to grow and re-differentiate into mature 
adipocytes again. This suggests that adipocytes can undergo cell turnover [11]. 
Adipocytes become mature and active through a process known as adipogenesis. 
Adipogenesis is defined as the differentiation of a fibroblast-like preadipocyte into a 
mature lipid-laden, insulin-sensitive adipocyte [12]. In vitro studies, primarily using 
mouse 3T3-L1 cell models, have described adipogenesis as occurring in six stages. These 
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stages include mesenchymal precursors, committed preadipocyte, growth-arrested 
preadipocyte, mitotic clonal expansion, terminal differentiation, and mature adipocyte 
[13]. The stage of mesenchymal precursor is characterized by proliferation and the ability 
to commit to different lineages. The committed preadipocyte phase is characterized by 
the proliferation of preadipocytes, the commitment to differentiation, and adapting a 
fibroblast-like morphology.  
Once grown to confluency, preadipocytes will arrest at the G0-to-G1 cell cycle 
transition due to the contact inhibition. During the mitotic clonal expansion stage (MCE), 
preadipocytes will reenter the cell cycle, stimulated by hormones such as insulin (Ins), 
dexamethasone (Dexa), and isobutylmethylxanthine (IBMX). MCE involves several 
cycles of cell division and literature has suggested that differentiation requires this 
external stimuli [14]. Terminal differentiation involves cell cycle arrest, the induction of 
several transcription factors for adipogenesis like peroxisome proliferator-activated 
receptor gamma (PPAR-γ), and transcriptional activation of adipocyte-specific genes. 
The final stage of adipogenesis is the mature adipocyte where the adipocyte forms a large 
lipid droplet, PPAR-γ becomes transcriptionally active, and adipocyte-specific genes are 
expressed [13]. This process of maturing preadipocytes can take 8 to 14 days. 
The adipocyte life cycle makes for an attractive target pathway for treating 
obesity for example, one can induce apoptosis of preadipocytes, maturing preadipocytes, 
and the apoptosis of mature adipocytes. Scientists have also targeted the maturation of 
preadipocytes phase to inhibit adipogenesis and the stimulation of lipolysis of mature 
adipocytes. The molecular and biological processes that occur during adipogenesis 
remain unclear. Another approach towards anti-obesity therapy is to focus on the 
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transdifferentiation of white adipose tissue to beige adipose tissue to increase energy 
expenditure in the form of heat.     
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Figure 1. Targeting the adipocyte life cycle for prevention and treatment of obesity 
[12]. 
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1.2.2 White Adipose Tissue versus Brown Adipose Tissue 
 There are two types of adipose tissue categorized by their antagonistic functions: 
white adipose tissue (WAT) stores excessive energy as triglycerides and brown adipose 
tissue (BAT) releases excessive energy in the form of heat. WAT is localized in humans 
subcutaneously and in the viscera. While classic BAT is thought to be present only in 
newborns, adults have BAT-like beige adipose tissue (BeAT) distributed throughout the 
axillary, paravertebral, mediastinal, upper abdominal regions, supraclavicular, and 
cervical areas [15].  
 White adipocytes can be distinguished from brown adipocytes by a large lipid 
droplet that predominates the cell and elongated mitochondria located within the thin 
cytoplasm. Brown adipocytes have smaller lipid droplets than white adipocytes. BAT 
contains an abundance of mitochondria that are large, spherical, and packed with laminar 
cristae. BAT also demands more vascular supply than that of WAT functioning for 
effective thermogenesis. The mitochondrial density and high vascularization of BAT is 
what gives the tissue its brown color [15].  
 It was once thought that brown and white adipocytes originate from the same 
mesenchymal progenitor cell, until recently, when scientists demonstrated that brown 
adipocytes arise from Myf5 muscle-like progenitor cells [16]. Brown adipocytes express 
specific markers like UCP1, PGC-1α, and PRDM16.  
 White adipocytes express specific proteins such as leptin and adiponectin. Leptin, 
the ob protein produced in WAT, expression levels are directly proportional to white fat 
mass and show a strong relationship with the size of adipocytes. The increase in 
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secretions and expression levels of leptin from adipocytes upregulates anabolic processes. 
Activation of β-adrenergic receptors and increases in the intracellular cyclic AMP 
(cAMP) levels inhibit leptin expression, in other words, catabolic processes are inhibited 
[17]. The differences between BAT and WAT contribute to their antagonistic roles in 
energy metabolism and homeostasis.  
1.2.3 Thermogenic Properties of BAT 
The abundance of mitochondria found in BAT contain respiratory chains that 
allow these cells to oxidize substrates at a high rate. The dissipation of heat produced 
from fatty acid oxidation makes BAT thermogenesis possible. In response to stress, like 
cold air or excessive energy, a mammal’s sympathetic nervous system will be activated 
and norepinephrine will be released. Norepinephrine then interacts with β-adrenergic 
receptors located on the plasma membrane of a brown adipocyte forming cAMP. cAMP 
is responsible for activating type 2 deiodinase, a catalyst that converts inactive thyroxine 
(T4) to the biologically active triiodothyronine (T3) in brown adipocytes. T3 serves to 
increase energy expenditure, increase mitochondrial functioning, and increase the basal 
metabolic rate of an individual. cAMP can also accelerate the amount of free fatty acids 
available to be used as fuel for thermogenesis and as an activator of UCP1 [18]. UCP1 
uncouples respiration from ATP synthesis and in turn, large amounts of energy is 
released in the form of heat.   
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1.2.4 Beiging of WAT: The New Brown Fat 
Recently, a third type of adipose tissue has been identified as beige adipose tissue 
(BeAT). These beige fat cells emerge from WAT as a result of the “browning/beiging” of 
mature adipocytes. Beige cells within white adipose depots do not share the same cellular 
lineage as classic brown adipocytes; instead, they arise from a non-Myf-5 cell lineage [2]. 
Research has demonstrated that UCP1 is not constitutively expressed in BeAT, like BAT, 
but that it is inducible and once induced, BeAT will exert its thermogenic functions.  
WAT can be transdifferentiated into BeAT under β-adrenergic stimulation and 
cold exposure [19]. Since the amount of BAT in the human body decreases with age, and 
body weight increases [15], it is ideal to target the browning of WAT for obesity therapy. 
1.3 Immunometabolism 
 In the obese state, adipose tissues produce a significantly large amount of pro-
inflammatory cytokines and adipokines secondary to its abundance of white adipocytes 
and pro-inflammatory immune cells such as ‘classically activated’ M1 macrophages. This 
is why obesity is associated with systemic, chronic, low-grade inflammation. In the lean 
state, ‘alternatively activated’ M2 macrophages are more abundant in WAT and secrete 
anti-inflammatory cytokines and catecholamines. M2 type macrophages have also been 
associated with maintaining insulin sensitivity. M1 macrophages comprise 10-15% of 
adipose tissue in lean states but in obese states, macrophages make up 40-50% of the 
stromal vascular cells in visceral adipose tissue [20]. 
 Monocytes are precursors to macrophages and macrophages can undergo 
polarization in response to their microenvironment. In obesity, interferon-γ (IFN-γ), and 
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lipopolysaccharide (LPS) polarize macrophages toward the M1 phenotype. M1 type 
macrophages secrete pro-inflammatory cytokines such as interleukin-6, tumor necrosis 
factor-α, and interleukin-12, as well as nitric oxide [20]. M1 macrophages are associated 
with killing responses [21].  
 The polarization of the M2 type macrophage is stimulated by interleukin-4 (IL-4). 
M2 type macrophages express arginase – 1, anti-inflammatory cytokines including, but 
not limited to, interlekin-10 (IL-10), interleukin-1 (IL-1) receptor antagonists, and 
catecholamines. Arginase – 1 is an enzyme involved in the urea cycle where it functions 
to hydrolyze arginine to urea and ornithine, removing nitrogen from the body. Ornithine 
can generate proline which synthesizes collagen. This production of collagen, regulated 
by arginase – 1, is said to have wound healing and tissue repair effects [22]. Arginase – 1 
is constitutively expressed in the liver but is inducible upon external stimulation and is 
regulated in macrophages. M2 macrophages can contribute to the browning of WAT but 
this mechanism is poorly understood [3]. 
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Figure 2. Cross-talk between adipocytes and immune cells in adipose tissue [20]. 
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1.4 Current Treatments for Obesity 
 The standard recommendations for weight loss include increasing physical 
activity, decreasing caloric intake, changing dietary habits, and behavior modifications 
such as counseling or support groups. Bariatric surgery is also an option but it is high risk 
and expensive. Though these lifestyle changes can result in weight loss, they do not 
ameliorate the obesity epidemic.  
 Pharmacotherapeutics approved as anti-obesity drugs on the market today act in 
one of two ways: decreasing fat accumulation and acting centrally to suppress appetite. In 
the past, anti-obesity drugs have been removed from the market due to adverse effects 
including sibutramine and amphetamines. Amphetamine was a concoction of other drugs 
making it addictive, increasing the risk of myocardial infarction, and sudden death. 
Sibutramine, an amphetamine analog, was removed from the market after it was 
associated with an increased risk of heart attack and stroke [23].  
The US Food and Drug Administration has recently approved several new weight 
loss drugs. Five new therapies include orlistat, lorcaserin, phentermine/topiramate, 
naltrexone/buproprion, and liraglutide [23]. Considering obesity is a global epidemic, the 
number of FDA approved medications to address this issue is limited. Additionally, the 
existing anti-obesity medications are accompanied with adverse side effects and do not 
directly target adipose tissue or energy expenditure, making these treatments less 
efficient.  
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1.5 Phytochemicals: Are They The Safer Alternative? 
 Natural health products have a long-standing reputation of serving as medications 
and healing therapies. Phytochemicals are characterized based on their structure and 
include polyphenols, alkaloids, and isoprenoids. There has been extensive research 
demonstrating that phytochemicals are anti-oxidants, anti-cancer agents, immune system 
activators, metabolism modulators, and more. Phytochemicals have also been evaluated 
for their efficacy in the treatment of obesity. Many phytochemicals such as 
guggulsterone, curcumin, and resveratrol inhibit adipogenesis, stimulate lipolysis in 
adipocytes, and even function as browning agents [12, 24, 25]. 
1.5.1 Xanthohumol 
Xanthohumol is a prenylated flavonoid found in the hops flower, Humulus 
lupulus. Hops are used to preserve and add flavor to beer. XN has already been identified 
to have anti-cancer, anti-diabetic and anti-oxidant characteristics [4]. Dr. Rayalam’s lab 
has previously reported that XN inhibits adipogenesis and increases lipolysis in 3T3-L1 
adipocytes [25].  
XN has been shown to possess anti-carcinogenic, anti-oxidant, and anti-diabetic 
properties [26-28]. It has been suggested that the chemical structure of XN is responsible 
for its wide range of biological activities. The XN molecule is comprised of two aromatic 
rings substituted with hydroxyl and methoxyl groups, and a prenyl unit (Fig. 3). Because 
of its prenyl and –OCH3 group, XN is highly lipophilic and has a strong affinity for 
biological membranes [29]. Hirata et al., reported that XN inhibits the cholesteryl ester 
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transfer protein (CETP), resulting in an increase in high density lipoprotein levels. This 
inhibitory effect can be attributed to XN’s prenyl group and chalcone structure [30].  
Costa et al., demonstrated that XN consumption in high-fat diet fed mice 
prevented weight gain, decreased blood glucose levels, triglyceride, and cholesterol 
levels, and improved insulin sensitivity. XN also activated the AMPK signaling pathway, 
suppressing lipogenesis [31]. Additionally, XN is suggested to be an agonist of the 
farnesoid X receptor through a selective bile acid receptor modulator, similar to the 
phytochemical guggulsterone. This interaction with FXR results in the amelioration of 
lipid and glucose metabolism [32]. XN increased the mRNA expression of TGR5, a G 
protein-coupled bile acid receptor, in mature 3T3-L1 adipocytes, indicative of its possible 
role in the TGR5 pathway [33]. Oral administration of XN improved inflammatory 
markers and the metabolic profile in diet-induced obese C57BL/6J mice [34]. However, 
XN’s beiging effects on adipocytes and the underlying mechanisms remain to be 
understood. 
In this study, we have shown that XN induces beiging of 3T3-L1 adipocytes both 
directly and indirectly, and these actions are dependent upon the activation of the AMPK 
pathway.  
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Figure 3. Chemical structure of xanthohumol. 
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1.6 AMPK as a Target for Metabolic Disorders 
AMPK is a master metabolic switch and is believed to be expressed in a number 
of tissues including BAT. The thermogenic activities of BAT are activated by AMPK 
[35]. BAT activation is stimulated in response to cold conditions resulting in the 
phosphorylation of AMPK to its active form to begin to increase thermogenesis. AMPK 
is an enzyme complex composed of three subunits, the catalytic α subunit and the two 
regulatory β and γ subunits. The α1 isoform is the predominant isoform expressed in 
adipose tissue [36]. AMPK is phosphorylated at Thr172 of the α subunit and as a result, 
becomes biological active [37].  
In our metabolic organs that function to maintain energy homeostasis, like 
adipose tissue, phosphorylated-AMPK (p-AMPK) inhibits anabolic processes and 
upregulates catabolic processes. p-AMPK works to enhance fatty acid oxidation by the 
phosphorylation of acetyl-CoA carboxylase, thereby increasing the incidence of fatty acid 
degradation [37]. AMPK’s role in adipose tissue metabolism has been characterized [38] 
but it remains unclear whether AMPK is involved in the beiging of white adipocytes.  
Provided the importance of AMPK in modulating energy homeostasis, little is 
known about the physiological roles of AMPK in brown and white adipose tissue, or the 
regulation of AMPK in these tissues. Understanding AMPK’s role in regulating BAT 
metabolism is attractive because of BAT’s unique ability to release excess energy in the 
form of heat via uncoupled metabolism. 
Recent studies propose that AMPK influences adipocyte functioning and the 
inflammatory environment of adipose tissues [39, 40]. Chronic nutrient overload creates 
Samuels  17 
 
stress in adipose tissue. This stress results in the accumulation of lipids in adipocytes in 
addition to the storage of fat in the liver, muscles, and pancreas. Consequently, this 
stimulates the innate immunity defense where pro-inflammatory cytokines are released 
and monocytes are recruited into adipose tissue[41].  
An increase in pro-inflammatory macrophage content of adipose tissue increases 
adiposity [42]. Activated AMPK has been suggested to suppress the pro-inflammatory 
environment and promote M2 macrophage polarization within adipose tissue [43]. Since 
obesity is characterized by chronic, low-grade inflammation, activating AMPK in adipose 
tissue may be found to be beneficial in improving the metabolic profile in obese states. 
In the current study, we aimed to elucidate the role of XN in brown-like adipocyte 
formation in 3T3-L1 adipocytes and to investigate the possible molecular mechanism 
underlying this process. It was also our goal to define XN-mediated polarization of 
macrophages and AMPK’s role in this process.  
Our data demonstrates that XN induces the beiging of adipocytes and polarizes 
macrophages toward the anti-inflammatory phenotype. These multi-faceted anti-obesity 
effects of XN are mediated via the AMPK signaling pathway.   
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Figure 4. Proposed pathway for xanthohumol-induced adipocyte beiging via the 
AMPK signaling pathway: (→) stimulatory, (┴) inhibitory, (↑) upregulation. 
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Chapter Two  
Xanthohumol-induced Beiging of 3T3-L1 Mature 
Adipocytes: Role of AMPK Signaling Pathway 
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Abstract 
 Xanthohumol (XN), a flavonoid compound extracted from the hop plant Humulus 
lupus, has been studied for its anti-cancer and anti-adipogenic effects. In this study, we 
have investigated the effects of XN on the inhibition of adipogenesis and the induction of 
browning in 3T3-L1 adipocytes. Furthermore, we provide evidence, for the first time, on 
the role of the adenosine monophosphate-activated protein kinase (AMPK) signaling 
pathway in XN-induced anti-obesity effects.  
Browning of white adipose tissue, WAT, is emerging as a novel approach to 
address obesity. AMPK is activated in response to stress-like exposure to cold and has 
been shown to induce browning of WAT. Treatment of 3T3-L1 adipocytes with XN 
decreased lipid content during adipogenesis and increased the expression of uncoupling 
protein 1 (UCP1), in a dose-dependent manner in mature adipocytes. XN further 
increased mitochondrial activity in mature adipocytes after 24 hours, suggesting 
browning of adipocytes.  
To demonstrate the role of AMPK pathway in XN-induced anti-obesity effects, 
mature adipocytes were treated with either 0.1% DMSO or XN 25µM in the presence or 
absence of dorsomorphin, an established inhibitor of the AMPK pathway, and 5-
Aminoimidazole-4-carboxamide ribonucleotide (AICAR), an AMPK stimulator. XN 
increased the expression of phospho-AMPK (p-AMPK) and this XN-induced increase in 
AMPK activation was diminished in the presence of dorsomorphin. On the other hand, 
co-incubation of XN plus AICAR demonstrated an additive effect on the activation of 
AMPK. Likewise, dorsomorphin reversed XN-induced inhibition of adipogenesis while 
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XN plus AICAR demonstrated an additive effect on the inhibition of lipid content during 
adipogenesis. Additionally, XN promoted lipolysis of mature 3T3-L1 adipocytes but this 
effect was also reversed in the presence of dorsomorphin. These results provide evidence 
for the potential role of AMPK pathway in XN-induced anti-obesity effects in 3T3-L1 
adipocytes. 
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2.1 Introduction 
Until recently, adipose tissue has been identified to function as a metabolic and 
endocrine organ, having both positive and negative characteristics. Excessive 
accumulation of adipose tissue leads to obesity, a chronic metabolic disease characterized 
by chronic, low-grade inflammation. Obesity increases the risk of developing 
hypertension, certain cancers, cardiovascular disease, musculoskeletal disorders, insulin 
resistance, as well as several other co-morbidities [10].  
At the onset of obesity, adipocytes become hypertrophic and hyperplasic. WAT is 
comprised of mature, lipid laden adipocytes, immune cells such as macrophages, 
preadipocytes, and stromal vascular cells. WAT lack mitochondria and UCP1, and thus 
thermogenic properties, unlike BAT. Thermogenesis has been shown to decrease 
adiposity and diabetes in both mice and adult humans [44-47]. An intermediate type of 
adipocyte is the “beige” or “brite” adipocyte. This cell type is functionally and 
morphologically similar to the brown adipocyte but is derived from white adipocytes via 
transdifferentiation or a process known as “beiging” in response to cold exposure or beta-
adrenergic stimuli [48].  
Phytochemicals have been recently proposed to act as beiging agents and are 
gaining the attention of scientists. Several phytochemicals such as resveratrol, curcumin, 
quercetin, and genistein have been demonstrated to be promising BAT activators or serve 
to increase thermogenesis therefore, treating obesity and the metabolic syndrome [49]. 
Literature has suggested that XN, a prenylated flavonoid found in hops and beer itself, 
induces apoptosis of mature adipocytes and inhibits adipogenesis in the mouse 3T3-L1 
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adipocyte cell line [50]. To the contrary, Mendes and colleagues claimed that XN does 
not improve the metabolic profile linked to obesity [51]. Therefore, we sought to explore 
XN’s potential anti-obesity effects in vitro.  
As a complex, multi-factorial, chronic disease, obesity develops from an 
imbalance of energy homeostasis. Consequently, adipocytes grow and expand. These 
processes are dependent on the regulation of adipogenesis. Furthermore, hyperplasic 
adipocytes also negatively impact the pathogenesis of obesity. Anti-obesity therapies that 
target the adipocyte life cycle or mature adipocytes call for an ideal tool in decreasing 
adiposity [12]. 
 AMPK is an energy gauge that, once activated, promotes catabolic pathways and 
inhibits anabolic pathways that consume ATP. Several studies have implicated the 
AMPK enzyme as a potential signaling target for obesity therapy [52, 53].  
AMPK can be activated by pharmacological interventions such as AICAR, 
metformin, phytochemicals, and hormones like adiponectin, catecholamines or the 
cytokine interleukin 6 [52, 54, 55]. AMPK has also been noted to be inhibited by 
dorsomorphin, a competitive ATP cell permeable pyrrazolopyrimidine derivative [56].  
Whether XN can activate AMPK and if AMPK signaling has a role in XN’s anti-
obesity effects remains to be defined. We hypothesize that the effects of XN in the 
beiging of white adipocytes is partly mediated by the activation of the AMPK signaling 
pathway. 
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2.2 Specific Aims   
 XN’s ability to inhibit adipogenesis, induce lipolysis, lower blood glucose and 
triglyceride levels, has been reported, however, XN’s effects on BAT activity or beiging 
of WAT has not been investigated. In this study, we have two specific aims (Figure 5). 
Specific aim 1:  To demonstrate the beiging effects of XN using 3T3-L1 adipocytes.  
Specific aim 2: To investigate AMPK’s possible role in XN-mediated beiging.  
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Figure 5. Working model for xanthohumol-induced beiging of white adipose tissue. 
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2.3 Materials and Methods 
2.3.1 Cell culture and differentiation  
 Dulbecco’s Modification of Eagle’s Medium (DMEM; Corning, Manassas, VA, 
USA) supplemented with 10% calf serum (CS; Invitrogen, Grand Island, NY, USA) and 
1% penicillin streptomycin (PS; Sigma-Aldrich, St. Louis, MO, USA) was used to culture 
3T3-L1 mouse embryo preadipocytes (Zenbio) at 37°C in a 5% CO2 incubator.  
Once confluent, cells were maintained in differentiation induction medium I (DMI) 
comprised of 1 mg/ml of insulin (Ins; Sigma-Aldrich, St. Louis, MO, USA), 5 µM of 
dexamethasone (Dexa; Sigma-Aldrich, St. Louis, MO, USA), 0.5 mM of 
isobuytlmethylxanthine (IBMX; Sigma-Aldrich, St. Louis, MO, USA), and 1 µM of 
rosiglitazone (Rosi; Sigma-Aldrich, St. Louis, MO, USA) for three days in DMEM plus 
10% fetal bovine serum (FBS; Invitrogen, Grand Island, NY, USA) and 1% PS. 
Following DMI, cells were then maintained in differentiation medium II (DMII) 
containing 10% FBS, 1% PS, 1 mg/ml of Ins, and 1 µM of Dexa. Unless otherwise stated, 
cells were maintained in DMII for 8-10 days before treatment and analysis and until cells 
matured with a minimum of 90% lipid droplet accumulation. Maintenance medium was 
changed every other day. XN 6.25 µM and XN 25 µM were the two optimal doses used 
in this study based on cell viability assays.  
2.3.2 Cytotoxicity  
 Mature 3T3-L1 adipocytes were treated with 0.1% dimethylsulfoxide (DMSO; 
Sigma-Aldrich, St. Louis, MO, USA) vehicle control or XN for 24 hours. Cell viability 
was measured using Prestoblue™ Cell Viability Reagent (ThermoFisher Scientific, 
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Grand Island, NY, USA) according to the manufacturer’s protocol. The absorbance of 
metabolically active cells was quantified 1 hour after incubation in the reagent using the 
Biotek Synergy HT (Winooski, VT, USA) microplate reader at 570nm.  
2.3.3 Immunoblot analysis 
 Proteins were lysed and extracted from mature 3T3-L1 adipocytes after treatment 
with 0.1% DMSO, XN 6.25-25 µM (XN; Tocris Bioscience, Bristol, UK), isoproterenol 
10 µM (Iso; Sigma-Aldrich, St. Louis, MO, USA), dorsomorphin 10 µM (Dorso; Abcam, 
Cambridge, MA), or 5-Aminoimidazole-4-carboxamide ribonucleotide 2 mM  (AICAR; 
Abcam, Cambridge, MA, USA) for 24 hours using ice cold RIPA Lysis and Extraction 
buffer complete with protease and phosphatase inhibitors (ThermoFisher Scientific, 
Grand Island, NY, USA).  
 Whole cell lysate was then prepared by centrifuging cells for 10 minutes at 
13,300g at 4°C. Following protein estimation, as determined by the Pierce BCA Protein 
Assay Kit (ThermoFisher Scientific, Grand Island, NY, USA), the proteins were diluted 
in 4X sample buffer and heated for 5 minutes at 95°C.  
After reducing and denaturing, proteins were loaded and separated on 4-20% SDS 
polyacrylamide gels and transferred to a polyvinylidene difluoride (PVDF) membrane 
using the Trans-blot Turbo system (Bio-Rad, Hercules, California, USA). The 
membranes were then blocked in Tris buffered saline plus 0.1% Tween 20 (TBS-T) 
containing 3-5% BSA blocking buffer for 1 hour at room temperature and then incubated 
in primary antibodies in TBS-T containing 3-5% BSA blocking buffer for 1 hour at room 
temperature.  
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The primary antibodies used in this study included: anti-UCP1, anti-CIDE-A, 
anti-TBX-1, anti-phospho-AMPK (Thr172), (all from Abcam, Cambridge, MA, USA), 
anti-PGC-1α, anti-ZIC1, mouse anti-α-tubulin (Novus Biologicals, Littleton, CO, USA), 
and mouse anti-β-actin (Santa Cruz Biotechnology, Cambridge, MA, USA).  
Following primary antibody incubation, the membranes were then washed three 
consecutive times with TBS-T and incubated with LiCor secondary antibodies (LiCor 
Biosciences, Lincoln, NE, USA) for 45 minutes at room temperature. The membranes 
were rinsed another three times, consecutively, with TBS-T, and fluorescent imaging was 
developed using the LiCor Odessey CLX imaging system (LiCor Biosciences, Lincoln, 
NE, USA). Relative protein levels were quantified using Image Studio Ver. 5.2 (LiCor 
Biosciences, Lincoln, NE, USA). 
2.3.4 Mitochondrial biogenesis  
 Mature 3T3-L1 adipocytes were treated with 0.1% DMSO, XN 6.25 µM, XN 12.5 
µM, XN 25 µM, and Iso 10 µM for 24 hours and incubated with Mitotracker® Green FM 
(Invitrogen, Grand Island, NY, USA) as per the manufacturer’s instructions. 
Mitochondrial activity was measured using the Biotek Synergy HT (Winooski, VT, USA) 
microplate reader at 516nm and images were captured using the EVOS FL Auto Imaging 
System (ThermoFisher Scientific, Grand Island, NY, USA) microscope. 
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2.3.5 Oil Red O staining 
 DMSO and XN treated cells were matured for 4-8 days, followed by washing 
with phosphate buffered saline (PBS), fixation with 10% formalin for 1 hour at room 
temperature, and washing again three times with deionized water. A 6:4 mixture of Oil 
Red O solution (0.6% Oil Red O dye in isopropanol) and water was added to the cells for 
20 minutes followed by a wash four times with deionized water. Finally, hematoxylin 
was layered over the cells and incubated for one minute, then rinsed. Lipid droplets were 
imaged under phase contrast using the EVOS FL Auto Imaging System (ThermoFisher 
Scientific, Grand Island, NY, USA) microscope. 
2.3.6 AdipoRed™ Adipogenesis Assay 
 Preadipocytes treated with 0.1% DMSO, XN 25 µM, Dorso 10 µM or AICAR 2 
mM on day 0 were treated every other day until day 8 of the adipocyte life cycle. Lipid 
accumulation was quantified using the AdipoRed™ assay (Lonza, USA) per the 
manufacturer’s protocol. Mature adipocytes treated with 0.1% DMSO, XN 25 µM, Dorso 
10 µM, or AICAR 2 mM were also assayed on day 8 for lipid quantification. Lipid 
quantification was obtained using the Biotek Synergy HT (Winooski, VT, USA) 
microplate reader at a fluorescence of 485/590 nm. 
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2.3.7 Statistical analysis 
 All data were expressed as the mean ± SEM, minimum n = 3. Comparisons were 
made by using one-way analysis of variance (ANOVA) on GraphPad Prism software, 
followed by Tukey’s post hoc tests. Statistical significance was reported as P < 0.05, P 
0.01, P < 0.001 or P < 0.0001.   
 
2.4 Results 
2.4.1 XN does not produce cytotoxic effects in 3T3-L1 adipocytes 
 Mature 3T3-L1 adipocytes were treated with 0.1% DMSO, XN 25µM and XN 50 
µM for 24 hours. Following incubation for 24 hours, XN was not significantly cytotoxic 
to adipocytes at the indicated doses (Fig. 6).  
2.4.2 XN induces beiging of mature 3T3-L1 adipocytes 
 To investigate the beiging effect of XN, 3T3-L1 adipocytes were used as a 
cellular model and stimulated with XN 6.25-25 µM and isoproterenol 10 µM as a 
positive control. XN 25 µM significantly increased the expression of beige/brown 
markers CIDE-A, ZIC1, and TBX-1 (Fig. 7). 
2.4.3 XN increases thermogenic marker expression and induces mitochondrial 
biogenesis in adipocytes 
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 To determine if XN increases mitochondrial biogenesis, a characteristic of 
browning, MitoTracker® Green FM was performed that specifically binds to 
mitochondria. As shown in Fig. 8, mitochondrial content was markedly elevated in XN-
treated groups and this was further confirmed by Western Blot analysis of PGC-1α, a 
central driver of mitochondrial biogenesis in adipocytes (Fig. 9). Furthermore, increased 
expression of mitochondrial uncoupling protein 1 (UCP1) (Fig.10), a thermogenic 
marker, support these findings and suggests further XN-induced beiging of mature 3T3-
L1 adipocytes.  
2.4.4 XN regulates lipid metabolism in 3T3-L1 adipocytes 
 To establish XN’s multifaceted anti-obesity effects on 3T3-L1 adipocytes, we 
examined whether XN promotes lipolysis and inhibits preadipocyte differentiation. 
Preadipocytes were treated with XN 6.25-25 µM and 0.1% DMSO vehicle control on day 
0 until day 8 of differentiation. As visualized by Oil Red O staining (Fig. 11), XN 
decreased the number and size of lipid droplets suggesting that XN inhibits adipogenesis 
and suppresses lipid accumulation.  
2.4.5 XN stimulates the phosphorylation of AMPK in mature 3T3-L1 adipocytes 
AMPK is an important regulator of metabolic homeostasis within a cell [57, 58]. 
A consequence of the activation of AMPK signaling is lipid metabolism modulation, 
mitochondrial biogenesis, and a decrease in blood glucose levels [58]. Therefore, we 
sought to investigate the effect of XN on AMPK phosphorylation. XN treatment of 
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mature 3T3-L1 adipocytes for one hour, significantly enhanced the expression levels of 
p-AMPK, similar to that of the AMPK agonist AICAR (Fig. 12).    
 
 
2.4.6 AMPK inhibition eliminates the thermogenic effects of XN on 3T3-L1 adipocytes 
 To identify the possible mechanism underlying the beiging effect of XN, the 
selective AMPK inhibitor, dorsomorphin, was used to determine UCP1 protein 
expression levels. When mature 3T3-L1 adipocytes were treated with XN 25 µM for one 
hour, results showed an increase in UCP1 expression. However, this effect was reversed 
by co-incubation of dorsomorphin with XN, suggesting that XN-induced beiging is 
mediated via AMPK signaling pathway (Fig 13).  
2.4.7 XN regulates adipogenesis through the AMPK pathway 
 Literature suggests that AMPK is crucial for the mediation of preadipocyte 
maturation [59]. We demonstrated that XN inhibits adipogenesis in 3T3-L1 cells but this 
inhibition is ameliorated in the presence of dorsomorphin (Fig. 14). Thus, XN-induced 
inhibition of adipogenesis is regulated through the AMPK pathway. 
2.4.7 XN stimulation of lipolysis is mediated through the AMPK pathway 
 Differentiated, mature adipocytes were exposed to XN, AICAR, and 
dorsomorphin for 72 hours. Fig. 15 shows the effects of these compounds on the 
induction of lipolysis in 3T3-L1 cells. AdipoRed assay results showed that XN decreased 
lipid content by 49% ± 6 when compared to the control. AICAR treatment alone 
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decreased lipid content by 8% ± 22 when compared to the control. To the contrary, XN in 
the presence of AICAR decreased lipid droplet size and content by 51% ± 7. 
Dorsomorphin increased lipid content significantly, by 61.5% ± 4.29. XN’s stimulation 
of lipolysis was abolished in the presence of dorsomorphin.  
2.5 Discussion 
 Obesity remains to be an epidemic worldwide and is a risk factor for several co-
morbidities. Current therapies targeting obesity are limited and are accompanied by 
unwanted side effects. Therapies that focus on BAT or BeAT activation make for an 
attractive target for the treatment of obesity and the metabolic syndrome [60]. In the 
present study, we have demonstrated that XN induces the brown fat-like phenotype from 
mature white adipocytes and drives thermogenesis through a dose-dependent elevated 
expression of brown fat markers such as UCP1, CIDE-A, ZIC1, and PGC-1α. Wu et al., 
suggested that TBX-1 is a beige fat specific marker and XN significantly upregulated the 
expression of TBX-1 indicating XN’s role in the induction of beiging white adipocytes 
[2].  
 A key characteristic of brown fat and beige fat is increased numbers of 
mitochondria [61]. Our data suggests that XN significantly increases mitochondrial 
biogenesis in mature 3T3-L1 adipocytes accompanied by the upregulation of PGC-1α, 
the central regulator of mitochondrial biogenesis and thermogenic programming [62]. In 
addition, UCP1 expression was elevated in 3T3-L1 adipocytes upon stimulation with XN, 
confirming mitochondrial oxidation and the acquisition of thermogenic properties [63].  
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 XN appears to inhibit the differentiation of preadipocytes and decrease lipid 
accumulation [25, 51] in 3T3-L1 cells. Our data confirms that XN-treated adipocytes are 
subjected to lipolysis and suppressed lipogenesis.   
 Previous studies provide evidence that pharmacological and genetic approaches to 
activate AMPK improves the metabolic profile [64-66]. Therefore, activation of the 
AMPK signaling pathway is crucial to achieving and maintaining energy homeostasis 
[67]. Our data demonstrates that XN significantly upregulates the expression of p-
AMPK, and this effect is ameliorated with the inhibition of p-AMPK. Flavonoids such as 
curcumin, chrysin, and quercetin induce the brown-like phenotype in 3T3-L1 adipocytes 
and this browning is mediated through the AMPK pathway [68]. To the contrary, it has 
been suggested that AMPK is activated but accompanied by constant levels of total 
AMPK during beiging of white adipocytes [36]. In this study, we have shown that the 
prenylated flavonoid, XN, significantly increased the expression of the thermogenic/ 
brown fat marker protein UCP1, and this upregulation is mediated partly through the 
activation of the AMPK pathway as evidenced by the arrest of UCP1 expression with co-
incubation of XN with dorsomorphin.  
Literature has supported the notion that there exists several pathways responsible 
for the beiging of white adipocytes, including numerous kinases, β-adrenergic receptor 
activation, bone morphogenetic protein, thyroid hormones, and fibroblast growth factor 
21 activation[52, 69]. To date, little is known about the extent of AMPK’s involvement in 
XN-mediated beiging of 3T3-L1 cells. Therefore, future molecular mechanistic studies 
are warranted to support our findings.  
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The anti-adipogenic effects of flavonoids have been suggested to be regulated via 
the AMPK signaling pathway in 3T3-L1 adipocytes [70, 71], however, the role of AMPK 
in regulating lipolysis has been controversial. Yin et al., reported that AMPK activation is 
essential in promoting lipolysis in vitro [72] while in vivo data demonstrated that AMPK 
activation is anti-lipolytic [73]. To identify its role in the XN-induced lipolytic pathway, 
we treated mature adipocytes with AICAR or dorsomorphin. Our data shows that XN 
suppressed adipocyte differentiation and reduced the accumulation of lipid content and 
lipid droplet size. Noteworthy, this anti-adipogenic and lipolysis effect of XN was 
abolished in the presence of dorsomorphin.  
Taken together, these results provide a novel insight into the molecular 
mechanism behind XN’s multi-faceted anti-obesity effects. In conclusion, the XN-
induced activation of AMPK results in the beiging of mature 3T3-L1 adipocytes, a 
downregulation of lipid content, and the inhibition of adipogenesis. 
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2.6 Figures 
 
Figure 6. XN did not induce cytotoxicity in 3T3-L1 adipocytes. Mature 3T3-L1 
adipocytes were treated with varying doses of XN for 24 hours, followed by 
measurement of cell viability using Prestoblue™ Cell Viability Reagent. All data are 
presented as mean ± SEM. Differences between treatment groups were determined by 
one-way analysis of variance (ANOVA) using GraphPad Prism software, followed by 
Tukey’s post hoc tests. Means denoted with different letters are statistically different P < 
0.05. 
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Figure 7. XN treatment induces expression of brown/beige fat markers. 3T3-L1 
mature adipocytes were treated with varying XN concentrations for 24 hours and 
expression of CIDE-A, ZIC1, and TBX-1 were determined by western blotting and 
quantified by densitometry analysis. All data are presented as mean ± SEM. Statistical 
significance between control and treatment groups is depicted as * P < 0.05, ** P < 0.01, 
and *** P < 0.001. 
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Figure 8. XN increases mitochondrial content in 3T3-L1 mature adipocytes. Various 
doses of xanthohumol (6.25, 12.5, and 25 µM) were administered to mature 3T3-L1 
adipocytes, followed by quantification of mitochondrial content using MitoTracker™ 
Green FM assay. All data are presented as the mean ± SEM. Means denoted with 
different letters are statistically different, P < 0.05. 
 
  
Samuels  39 
 
 
    
Figure 9. XN increases the expression of PGC-1α, a regulator of mitochondrial 
metabolism. Protein expression levels of PGC-1α in 3T3-L1 adipocytes after 24 hours of 
treatment with XN or isoproterenol. All data are presented as mean ± SEM. Statistical 
significance between control and treatment groups is depicted as * P < 0.05, *** P < 
0.001. 
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Figure 10. XN treatment upregulates UCP1 expression. Adipocytes were treated with 
XN or isoproterenol, and UCP1 expression levels were measured. All data are presented 
as mean ± SEM. Statistical significance between control and treatment groups is shown 
as * P < 0.05, and ** P < 0.01. 
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Figure 11. XN inhibits preadipocyte differentiation and adipogenesis. Oil Red O 
staining was performed to assess the maturation of 3T3-L1 adipocytes. XN treatment 
suppresses lipid accumulation in a dose-dependent manner. All data are presented as 
mean ± SEM. Statistical significance between control and treatment groups is shown as * 
P < 0.05. 
 
  
Control   XN 6.25µM    XN 25 µM 
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Figure 12. Effect of XN, dorsomorphin, and AICAR on AMPK activation. Mature 
adipocytes were treated for one hour and p-AMPK protein expression levels were 
measured. All data are presented as the mean ± SEM. Means denoted with different 
letters are statistically different, P < 0.05.  
Samuels  43 
 
 
 
Figure 13. XN-mediated upregulation of UCP1 is decreased in the presence of 
AMPK inhibitor, dorsomorphin. AICAR (2 mM) and dorsomorphin (10 µM) were 
incubated with mature adipocytes for one hour, and protein expression levels were 
determined by Western blotting. All data are presented as mean ± SEM. Statistical 
significance between control and treatment groups is shown as * P < 0.05.  
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Figure 14. XN-induced inhibition of adipogenesis is reversed in the presence of 
AMPK inhibitor, dorsomorphin. 3T3-L1 preadipocytes were treated on day 0 until day 
6 of maturation. Lipid accumulation was quantified by AdipoRed assay. All data are 
presented as the mean ± SEM. Means denoted with different letters are statistically 
different, P < 0.05. 
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Figure 15. Dorsomorphin reversed the XN-induced decrease in lipid content in 
mature 3T3-L1 adipocytes. Mature 3T3-L1 adipocytes were treated on day 10 for 72 
hours. Lipid accumulation was quantified by AdipoRed assay. All data are presented as 
the mean ± SEM. Means denoted with different letters are statistically different, P < 0.05. 
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Chapter Three 
 
Xanthohumol Mediated Polarization of RAW264.7 
Macrophages is Partly Mediated through the AMPK 
Signaling Pathway 
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Abstract 
Anti-inflammatory, anti-oxidant, and anti-cancer effects of xanthohumol (XN), a 
prenylated chalcone extracted from common hop plants, are gaining attention and 
research has been expanding on the beneficial effects of this compound. In this study, we 
have investigated the anti-inflammatory effects of XN using a mouse monocytic cell line, 
RAW264.7. We hypothesized that the anti-inflammatory effects of XN are due to M2 
polarization of macrophages which, in turn, is mediated partly through the adenosine 
monophosphate-activated protein kinase (AMPK) signaling pathway.  
Our results suggest that XN upregulated the secretion of interleukin 10 (IL-10), a 
signature cytokine for M2 polarization, in RAW264.7 cells in a dose-dependent manner. 
We further demonstrated that XN increased arginase-1 expression, a marker for M2 
polarization, and failed to increase inducible nitric oxide synthase (iNOS) expression, a 
marker for M1 polarization. XN decreased interferon-γ (IFN-γ) induced elevation of 
nitrite release, indicating the inhibitory effects of XN against M1 polarization. 
Additionally, XN increased the secretion of catecholamines from macrophages 
comparable to interleukin 4 (IL-4), an inducer of the M2 phenotype. Finally, XN and 
AICAR upregulated the expression of p-AMPK and arginase-1 in RAW264.7 cells, 
indicating the role of AMPK signaling pathway in XN-induced effects.  
Taken together, these results provide evidence for the anti-inflammatory 
properties of XN – mediated induction of M2 polarization. The M2 macrophage mediated 
anti-inflammatory effects, coupled with catecholamine secretion, and previously anti-
adipogenic effects, makes XN an attractive molecule to study its beneficial effects on 
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metabolic diseases, like obesity and diabetes which are associated with underlying 
chronic, low-grade inflammation. 
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4.1 Introduction  
Literature suggests that the imbalance of certain immune cells like macrophages 
and inflammatory adipokines, mediates the systemic inflammation that contributes to 
obesity [10, 74]. Macrophages respond to infection or the accumulation of dysfunctioning 
cells, which play a pivotal role in the regulation of inflammatory responses. Therefore, 
therapies that target macrophages may prevent or control inflammatory-mediated 
diseases, such as obesity.  
Monocytes can undergo polarization towards either a pro-inflammatory 
macrophage or an anti-inflammatory macrophage in response to their microenvironment 
[75]. Classically activated M1 macrophages, stimulated by Th1 cytokines like IFN-γ or 
the endotoxin lipopolysaccharide (LPS), produce effector molecules such as nitrogen 
intermediates and inflammatory cytokines. Alternatively activated M2 macrophages, 
stimulated by Th2 cytokines like IL-4, are characterized by their ability to produce 
catecholamines, arginase – 1, and IL-10 [76]. 
 Flavonoids have been implicated in mediating inflammatory responses [77]. To 
date, research on XN’s potential to regulate macrophage polarization is scarce. Our data 
shows that XN promotes monocytes to polarize towards the anti-inflammatory M2-like 
phenotype.    
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AMPK is a central controller of fatty acid, cholesterol, and glucose homeostasis 
through the phosphorylation of acetyl-CoA carboxylase, glycogen synthase, glucose 
transporter 4, HMG-CoA reductase, hormone sensitive lipase, and the mammalian target 
of rapamycin [64]. Adipose tissue macrophages (ATM) play a key role in obesity-
induced inflammation. With increased pro-inflammatory cytokines in the obese state 
comes the activation of inflammatory pathways in metabolic tissues [78].  
 Macrophages are heterogenetic in function and shift their properties and 
activation state based on their microenvironment. Activated AMPK has been shown to 
inhibit pro-inflammatory macrophage functioning and promote anti-inflammatory 
macrophage processes [43]. A potential role of AMPK in the suppression of 
inflammatory responses has been suggested using pharmacological approaches. To this 
end, we investigated the role of AMPK in the regulation of macrophage activity in 
response to XN stimulation. We demonstrate that AMPK is rapidly activated by XN in 
RAW264.7 cells and that AMPK mediates the macrophage inflammatory function. 
4.2 Specific Aims 
 Several flavonoids have been implicated in their ability to act as anti-
inflammatory agents [79]. Macrophages have also been identified to release 
catecholamines as modulators of immune responses [80]. Macrophage polarization is a 
hot topic in the quest for new anti-obesity therapies.  
As an energy sensor, AMPK is responsive to increased AMP/ATP ratios, 
pathogenic stressors, or energy imbalances. Recently, AMPK has been suggested to play 
a crucial role in regulating immune responses [65]. However, to date, XN and its 
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relationship with AMPK in modulating inflammatory responses has not been identified. 
In the current study, we will investigate whether XN regulates macrophage polarization 
and catecholamine secretion under the regulation of the AMPK pathway.  
Specific Aim 1: To investigate the effects of XN on the polarization of RAW264.7 cells. 
Specific Aim 2: To investigate the role of AMPK pathway in XN-induced polarization of 
RAW264.7 cells. 
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Figure 16: Working model for XN-mediated polarization of macrophages. 
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4.3 Materials and Methods 
4.3.1 Cell culture 
 The murine monocytic cell line, RAW264.7, was cultured in DMEM containing 
10% FBS and 1% PS at 37°C in a 5% CO2 incubator. Medium was replaced every other 
day. Cells were passaged at passage numbers 4 or 5 every four days in 0.25% trypsin plus 
EDTA. RAW264.7 cells were seeded at a density of 1.0 x 106/mL in 6-well plates. Once 
the cells reached 100% confluency, they were treated with 0.1% DMSO, XN 6.25 µM or 
25 µM, IFN-γ 10ng/mL, or IL-4 20ng/mL for 24 hours. To investigate AMPK’s role in 
XN-mediated polarization, RAW264.7 cells were treated with 0.1% DMSO, XN 6.25 µM 
or 25 µM, AICAR 2 mM, dorsomorphin 10 µM, or IL-4 20ng/mL for one hour. 
4.3.2 Cytotoxicity  
 Confluent RAW264.7 cells were treated with 0.1% DMSO vehicle control or XN 
for 24 hours. Cell viability was measured using Prestoblue™ Cell Viability Reagent 
according to the manufacturer’s protocol. The absorbance of metabolically active cells 
was quantified 1 hour after incubation in the reagent using the Biotek Synergy HT 
microplate reader at 570nm.  
4.3.3 Immunoblot analysis 
 Proteins were lysed and extracted from RAW264.7 macrophages after treatment 
with 0.1% DMSO, XN 6.25-25 µM, IFN-γ 10ng/mL, or IL-4 20ng/mL for 24 hours or 
AICAR 2 mM or dorsomorphin 10 µM for one hour. Details are provided in chapter two 
(page 25).  Primary antibodies included: anti-iNOS, anti-β-actin (Santa Cruz 
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Biotechnology, Cambridge, MA, USA), anti-arginase – 1, and p-AMPK (Thr172) (all 
from Abcam, Cambridge, MA, USA). 
4.3.4 Enzyme-linked Immunosorbent Assays 
 Catecholamine levels in culture medium of XN and IL-4 treated samples were 
determined by ELISA, following the manufacturer’s protocol (Blue Gene for Life 
Science; Shanghai, China). Monoclonal mouse anti-catecholamine antibodies were used 
as capturing antibodies.  
The product of the enzyme-substrate reaction produces a color change and these 
color changes were determined via the Synergy Biotek HT microplate reader at 450nm. 
Standard curves were utilized to analyze the color intensity with the concentration of 
catecholamine secretion from the standards. 
 For IL-10 levels, culture supernatants of XN and IL-4 treated RAW264.7 
macrophages were processed following the manufacturer’s instructions using a mouse IL-
10 ELISA kit (R&D Systems; Minneapolis, MN, USA).  
4.3.5 Nitrite Release Assay 
 XN, IFN-γ with or without XN, and IL-4 RAW264.7 culture supernatants were 
analyzed for nitrite release based on the Greiss reaction (Promega; Madison, WI, USA). 
Nitrite accumulation is an indicator of nitric oxide synthesis, and this accumulation is 
responsible for the cytotoxic mediators released from macrophages [81].  
Culture supernatant (50uL) was incubated at room temperature with Greiss 
reagent in a 96-well plate. After 10 minutes, absorbance was read on the Synergy Biotek 
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HT microplate reader at a wavelength of 520nm. Nitrite concentrations were calculated in 
comparison to a standard curve. 
4.3.6 Statistical analysis 
 All data were expressed as the mean ± SEM. All assays were performed in 
triplicate for a minimum of three independent experiments. Comparisons were made by 
using one-way ANOVA on GraphPad Prism software, followed by Tukey’s post hoc 
tests. Statistical significance was reported as * P < 0.05, ** P < 0.01, *** P < 0.001 or 
**** P < 0.0001.   
 
4.4 Results 
4.4.1 High dose XN decreases cell viability in RAW264.7 cells 
 The biological functions of a cell can largely depend on its viability. The effect of 
XN on the viability of RAW264.7 cells is depicted in Fig. 17. At low dose ranges (6.25, 
12.5, and 25 µM), XN had no significant effect on cell viability after 24 hours of 
treatment. However, at higher doses (50 and 75 µM), XN significantly decreased cellular 
viability of RAW264.7 cells by 37% ± 0.65 and 43% 0.65, respectively. Thus, XN 6.25 
and 25 µM was employed in our experiments.  
4.4.2 XN treatment leads to M2 macrophage polarization in RAW264.7 cells 
 It has been recently recognized that XN has anti-inflammatory properties [82]. To 
study XN’s possible anti-inflammatory effects in macrophage polarization, RAW264.7 
cells were stimulated with XN or IL-4 for 24 hours.  
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Arginase – 1, an anti-inflammatory M2 macrophage marker, protein expression 
levels were measure via Western blotting. Our results show that XN significantly 
upregulates the expression of arginase – 1, in a dose-dependent manner (P < 0.0001). 
Furthermore, XN 25 µM exhibited pronounced arginase – 1 upregulation comparable to 
that of IL-4, a positive control for M2 macrophage polarization (Fig. 18). These results 
suggest that XN polarizes RAW264.7 cells towards the anti-inflammatory phenotype. 
4.4.3 XN induces catecholamine and IL-10 secretion from RAW264.7 cells 
 To investigate whether XN stimulates IL-10 and free catecholamine secretion 
from macrophages, RAW264.7 cells were treated with 0.1% DMSO control, XN 6.25-25 
µM, or IL-4 for 24 hours. XN significantly increases the release of catecholamines (Fig. 
19) and IL-10 (Fig. 20) levels in a dose-dependent manner, providing novel evidence for 
XN-induced M2 polarization. 
4.4.4 XN inhibits M1 polarization in RAW264.7 cells 
 The effects of XN on iNOS expression in macrophages stimulated with IFN-γ 
were investigated in RAW264.7 cells treated with XN in the presence or absence of IFN-
γ. As shown in Fig. 21A, iNOS protein expression was increased in IFN-γ stimulated 
RAW264.7 cells. XN at 25 µM decreased IFN-γ-induced upregulation of iNOS thus, 
inhibiting M1 polarization. IFN-γ activated macrophages significantly induced the release 
of nitrite but this effect was suppressed by XN (Fig. 21B). 
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4.4.5 XN activates AMPK in RAW264.7 cells 
 We performed Western blot analyses to evaluate the effect of XN on AMPK 
phosphorylation in XN, IL-4, AICAR, and dorsomorphin treated RAW264.7 cells. We 
first examined whether XN led to AMPK activation after one hour of treatment. Fig. 22 
shows that XN significantly upregulated the expression of p-AMPK. Additionally, 
AICAR increased the expression of p-AMPK. In contrast, dorsomorphin attenuated the 
activation of p-AMPK in RAW264.7 cells.  
4.4.6 XN-induced M2 polarization is dependent upon the activation of AMPK signaling 
pathway 
 We next evaluated the impact of enhanced AMPK activation on macrophage 
inflammatory activity. RAW264.7 cells were treated with XN, AICAR, or IL-4 and 
analyzed for arginase – 1 protein expression. AICAR treated RAW264.7 cells displayed 
significant amounts of arginase – 1 expression comparable to that of both IL-4 and XN 
(Fig. 23). This data suggests that AMPK regulates XN-induced macrophage polarization.  
 
4.5 Discussion 
 Obesity, a central modulator of the metabolic syndrome, is closely linked with the 
state of chronic, low-grade inflammation. In adipose tissue, excessive energy intake 
results in pro-inflammatory macrophages infiltration and a shift in the phenotype 
polarization of macrophages. Literature has demonstrated that disruption in the 
expression of pro-inflammatory cytokines released by M1 macrophages relieves adipose 
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tissue inflammation and dysregulation [83]. To this end, it was our goal to examine the 
effects of XN on macrophage polarization. 
Macrophages are well characterized key regulators of the inflammatory response 
[84, 85]. Numerous studies have reported that macrophage infiltration in adipose tissue 
initiates and accelerates the cycle of inflammation within the obese state [42, 86]. Gordon 
et al., reported that both pro-inflammatory and anti-inflammatory macrophages reside in 
the tissue of obese persons [87]. Moreover, it has been accepted that the manipulation of 
the M1/M2 ratio, such that M1 macrophages are decreased in numbers and M2 
macrophages are increased, ameliorates adipose tissue inflammation [88]. In the current 
study, we demonstrate that XN ameliorates inflammation and regulates macrophage 
polarization through the AMPK signaling pathway. 
XN, a hops flavonoid, has been studied extensively for its anti-carcinogenic, anti-
oxidant, and anti-diabetic properties [4]. XN has also been reported to inhibit iNOS 
expression resulting in suppressed nitric oxide production in macrophages [89]. Adipose 
tissue marked with inflammation, orchestrated by ATM recruitment, is the central event 
initiating the metabolic syndrome [78]. To this end, we investigated whether XN 
polarizes RAW264.7 cells and the molecular mechanism behind it.  
Recent studies have implicated flavonoids as having potent anti-inflammatory 
properties. The dietary flavonoid quercetin was shown to prevent M1 polarization and 
inflammation of ATMs [90]. Resveratrol exerts anti-inflammatory effects on adipose 
tissue by attenuating tumor necrosis factor-α in visceral white adipose tissue macrophage 
release in mice [91]. Gao et al., reported that curcumin induces M2 polarization by IL-4 
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or IL-13 secretion in RAW264.7 cells [92]. In accordance with these findings, our data 
show that XN promotes RAW264.7 cells towards the anti-inflammatory phenotype as 
demonstrated by increased arginase – 1 expression, catecholamine, and IL-10 secretion. 
Conflictingly, isoliquiritigenin, a flavonoid from licorice, has been demonstrated to 
inhibit M2 polarization [93]. 
To further identify XN’s anti-inflammatory characteristics, we showed that XN 
attenuates pro-inflammatory mediators in RAW264.7 cells. IFN-γ-induced iNOS protein 
expression was reversed by XN. Furthermore, XN suppressed the release of nitrite in 
IFN-γ stimulated RAW264.7 macrophages. These results are suggestive of XN’s 
capability to prevent the polarization of macrophages towards the pro-inflammatory M1-
like phenotype. In conclusion, XN could improve obesity associated inflammation via 
regulation of the M1/M2 ratio in adipose tissue. Therefore, identifying signaling 
pathways that regulate macrophage polarization can help lead to strategies for the 
modification of macrophage behavior.  
The aim of this study was focused on addressing the hypothesis that the energy 
sensor, AMPK, serves as a regulator of inflammation in macrophages. Inflammation is 
the orchestrator in obesity pathogenesis and macrophage inflammation is the key 
component of obesity-induced inflammation. We believe that the signaling protein, 
AMPK, modulates immunometabolism because it is abundantly expressed in both 
adipocytes and macrophages, regulated by inflammatory stimuli, and regulates free fatty 
acid metabolism and the inflammatory response.  
Samuels  60 
 
 AMPK inhibits anabolic processes and activates catabolic processes once 
activated. A proposed role for AMPK in the regulation of inflammatory responses is 
supported by the use of AICAR; AICAR was shown to suppress the synthesis of iNOS by 
macrophages and adipocytes [94]. Several activators of AMPK have been identified to 
decrease pro-inflammatory mediators such as IFN-γ and tumor necrosis factor-α [94-96]. 
Furthermore, Sag et al., reported that AMPK promotes macrophages towards the anti-
inflammatory M2 phenotype [43]. This supports our results that XN and AICAR 
upregulated p-AMPK and arginase – 1 levels in RAW264.7 cells. These results indicate 
that XN-mediated macrophage polarization is dependent upon the activation of the 
AMPK signaling pathway.  
Our data indicate that AMPK is a regulator of immunometabolism in RAW264.7 
cells stimulated with XN. Disturbances of AMPK signaling during adipose tissue 
dysfunction could be linked to the over-productive activation of inflammatory signaling 
in obesity. 
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4.6 Figures 
 
Figure 17. Effect of XN on RAW264.7 cellular viability. RAW264.7 cells were treated 
with varying concentrations of XN for 24 hours and cell viability was measured by 
Prestoblue™ Cell Viability Reagent. All data are presented as the mean ± SEM. Means 
denoted with different letters are statistically different, P < 0.05.  
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Figure 18. Effect of XN on arginase – 1 protein expression levels. RAW264.7 cells 
were treated with varying concentrations of XN and IL-4 as a positive control and 
arginase – 1 expression was determined by Western blot. All data are presented as mean 
± SEM. Statistical significance between control and treatment groups is represented as 
*** P <0.001, **** P < 0.0001. 
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Figure 19. XN induces catecholamine secretion in RAW264.7 cells. RAW264.7 cells 
were treated with vehicle, XN, or IL-4 for 24 hours and catecholamine synthesis was 
examined. All data are presented as the mean ± SEM. Means denoted with different 
letters are statistically different, P < 0.05. 
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. 
Figure 20. Effect of XN on IL-10 secretion in RAW264.7 cells. All data are presented 
as mean ± SEM. Means denoted with different letters are statistically different, P < 0.05. 
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A.   
B.  
Figure 21. XN prevents M1 polarization in RAW264.7 cells. RAW267 cells were 
treated with XN, IL-4, or IFN-γ in the presence or absence of XN for 24 hours. A. XN 
downregulated IFN-γ-induced iNOS expression. B. XN suppressed nitrite release in IFN-
γ activated RAW264.7 macrophages. All data are presented as mean ± SEM. Means 
denoted with different letters are statistically different, P < 0.05. 
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Figure 22. Effect of XN on p-AMPK protein expression. RAW264.7 cells were treated 
with XN, AICAR, IL-4, or dorsomorphin for one hour and p-AMPK expression levels 
were assessed by Western blotting. All data are presented as mean ± SEM. Statistical 
significance between control and treatment groups is represented as * P < 0.05. 
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Figure 23. Effect of XN and AICAR on arginase-1 expression. RAW264.7 cells were 
treated with AICAR or XN for one hour and arginase-1 protein expression levels were 
measured via Western blotting. All data are presented as mean ± SEM. Statistical 
significance between control and treatment groups is represented as * P < 0.05, *** P < 
0.001, **** P < 0.0001. 
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Chapter Four 
 
Direct and Indirect Effects of Xanthohumol on the 
Induction of Beiging in 3T3-L1 adipocytes  
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6.1 Introduction 
 A marked feature of obesity is hypertrophic and hyperplasic adipocytes, and 
adipose tissue that is mainly comprised of pro-inflammatory M1 macrophages. 
Adipokines and cytokines derived from adipocytes and macrophages, respectively, cross-
talk may result in the metabolic syndrome. It has been proposed that the paracrine loop, 
with the key players being free fatty acids and pro-inflammatory cytokines, aggravates 
inflammation and promotes the hypertrophy of adipocytes [83]. 
 Noteworthy, similar changes in inflammation are remarkable in fat depots [97]. 
Adipocytes analyzed for gene expression profiles obtained from obese mice and humans 
showed that macrophages contribute the majority of pro-inflammatory cytokines [42].  
These observations lead to the conclusion that adipose tissue macrophages are the sole 
source of inflammation in obesity.  
 Mammals sustain energy homeostasis via thermogenesis, activated by cold 
exposure. When the central nervous system detects cold temperatures, the sympathetic 
nervous system will become activated and release catecholamines in BAT and WAT 
[98]. This release of catecholamines stimulates thermogenesis in brown/beige adipocytes. 
Nguyen et al., demonstrated that M2 macrophages regulate thermogenesis and in turn, the 
beiging of white adipocytes [76]. 
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With this, we aim to investigate the cross-talk between adipocytes and 
macrophages within a transwell co-culture system to measure beiging stimulated by XN, 
and determine inflammatory changes. Our data suggests that XN and IL-4 induced UPC1 
expression and increased mitochondrial biogenesis in adipocytes co-cultured with 
macrophages, suggesting that RAW264.7 cells mediated XN-induced beiging of 
adipocytes. Furthermore, XN stimulated the secretion of catecholamines and IL-10 in the 
co-culture system, confirming the acquisition of the M2 macrophage phenotype. 
6.2 Specific Aims 
 Adipose tissue is characterized by excessive inflammation in the obese state. The 
paracrine loop between adipocytes and macrophages exacerbates this inflammation in 
obese adipose tissue. Phytochemicals have been identified to have anti-adipogenic and 
anti-inflammatory effects but little is known about the effect of XN within a co-culture 
system.  
Specific Aim 1: To establish a co-culture system comprised of 3T3-L1 adipocytes and 
RAW264.7 macrophages. 
Specific Aim 2: To demonstrate direct and indirect effects of XN leading to enhanced 
induction of beiging in 3T3-L1 adipocytes. 
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Figure 24. Working model demonstrating the direct and indirect effects of XN on 
the induction of beiging in WAT. 
  
Samuels  72 
 
4.3 Materials and Methods 
4.3.1 Cell Culture and Differentiation of 3T3-L1 adipocytes and RAW264.7 cells 
Detailed cell culturing for 3T3-L1 adipocytes and RAW264.7 cells are described 
in chapter two (page 30) and chapter three (page 6), respectively.  
4.3.2 Transwell Co-culture System 
3T3-L1 preadipocytes were grown to confluency in 6-well plates and 
differentiated to mature adipocytes as described above. Cells were then cultured in a 
transwell system, on day 5 of the adipocyte maturation cycle, with 3T3-L1 cells in the 
lower chamber and RAW264.7 cells seeded onto the 0.4µm cell insert (Corning 
Incorporated; Kennebunk, ME, USA). The insert of the transwell is porous in that these 
pores are small enough to prevent the passage of most cell types, yet large enough to 
permit the passage of small molecules like cytokines or adipokines. Within the co-culture 
system, RAW264.7 cells were directly treated with 0.1% DMSO vehicle control, XN, or 
IL-4 for 24 hours. 
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Figure 25. Illustration of transwell co-culture system.  
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6.3.4 Immunoblot Analysis 
Immunoblot analysis was carried out as described in chapter 2 (page 25).  
6.3.5 Mitochondrial biogenesis  
 Mature 3T3-L1 adipocytes co-cultured with RAW264.7 cells were treated with 
0.1% DMSO, XN25 µM, or IL-4 20 ng/mL for 24 hours and incubated with 
Mitotracker® Green FM (Invitrogen, Grand Island, NY, USA) as per the manufacturer’s 
instructions. Mitochondrial activity was measured using the Biotek Synergy HT 
(Winooski, VT, USA) microplate reader at 516nm and images were captured using the 
EVOS FL Auto Imaging System (ThermoFisher Scientific, Grand Island, NY, USA) 
microscope. 
6.3.6 Enzyme-linked Immunosorbent Assays 
Detailed methods are described in chapter three (page 51).  
6.3.7 Statistical analysis 
 All data were expressed as the mean ± SEM. All assays were performed in 
triplicate for a minimum of three independent experiments. Comparisons were made by 
using One-way ANOVA on GraphPad Prism software, followed by Tukey’s post hoc 
tests. Statistical significance was reported as * P < 0.05, ** P < 0.01, ***P < 0.001 or 
**** P < 0.0001.   
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6.4 Results 
6.4.1 Enhanced levels of UCP1 in 3T3-L1 adipocyte-macrophage co-culture upon XN 
stimulation 
 We investigated the expression of UCP1 within mono-cultured adipocytes and co-
cultured RAW264.7 cells and white adipocytes. We observed less pronounced levels of 
UCP1 protein expression in XN treated 3T3-L1 adipocytes cultured alone (Fig. 26A) than 
in XN-stimulated 3T3-L1 mature adipocytes co-cultured with RAW264.7 cells (Fig. 
26B). Therefore, macrophages had an indirect impact on the beiging of differentiated 
adipocytes. 
6.4.2 XN increased mitochondrial biogenesis in 3T3-L1 adipocytes co-cultured with 
RAW264.7 macrophages 
 Because mitochondrial biogenesis is a feature of brown/beige adipocytes, we 
sought to investigate mitochondrial biogenesis activity within this co-culture system.  
Our data show that XN induced the upregulation of mitochondrial biogenesis in 3T3-L1 
adipocytes co-cultured with RAW264.7 macrophages, P < 0.05 (Fig. 27). This confirms 
beiging in this co-cultured transwell model.  
6.4.3 XN induces catecholamine secretion in co-cultured cells 
 Next, to investigate whether this beiging of 3T3-L1 adipocytes co-cultured with 
RAW264.7 cells was a result of macrophage polarization, we first examined the effect of 
XN on catecholamine secretion. The release of catecholamines into the co-culture 
medium increased with 24 hours of XN treatment (Fig. 28). Interestingly enough, these 
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effects were not more pronounced than catecholamine secretion in RAW264.7 
macrophages cultured alone (Fig. 19).  
6.4.4 Indirect contact between macrophages and adipocytes enhances secretion of anti-
inflammatory IL-10 levels 
 To determine if anti-inflammatory IL-10 secretion is regulated by paracrine 
communications, we co-cultured RAW264.7 macrophages, treated with XN or IL-4, with 
3T3-L1 adipocytes. Significant differences in IL-10 secretion levels were found when 
comparing direct (Fig. 20) and indirect macrophage-adipocyte co-cultures (Fig. 29), 
indicating that the co-culturing of cells in transwells, increased XN-induced IL-10 levels 
by 551%.  
Noteworthy, when comparing IL-4-stimulated RAW264.7 mono-cultured IL-10 
levels to co-cultured IL-10 levels, IL-10 secretion levels were more pronounced by 
1,644%, suggesting that adipocytes may secrete IL-10 [99] and XN is mediating 
inflammatory responses in both cell lines.  
 
6.5 Discussion 
 Obesity is associated with chronic, low-grade inflammation. Studies have 
demonstrated that dysfunctional adipose tissue is infiltrated with pro-inflammatory 
macrophages [42]. In the current study, we developed an in vitro transwell co-culture 
system comprised of differentiated 3T3-L1 adipocytes and RAW264.7 macrophages 
stimulated with XN or IL-4.  
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 In the lean state, adipose tissue is comprised mostly of M2-like macrophages 
while in the obese state, M1-like macrophages infiltrate adipose tissue. This infiltration 
creates the state of chronic, low-grade inflammation marked by obesity and this 
polarization state is characterized by secretions of pro-inflammatory cytokines [100]. 
Relative reductions in type 2 immunity may generate increases in pro-inflammatory 
macrophage polarization in obesity, influencing adipose tissue dysfunction and hormone 
response. 
Studies have proposed that M2 macrophages and type 2 immune signaling 
pathways leads to the beiging of white fat [76, 101]. It has been demonstrated that IL-4 
induces the expression of tyrosine hydroxylase, the rate-limiting enzyme in the synthesis 
of catecholamines, in M2 macrophages, increasing beiging of white adipose tissue [101]. 
In the present study, we observed a lack of significant IL-4-stimulated catecholamine 
secretion within the adipocyte-macrophage co-culture system, whereas unpublished data 
from Dr. Rayalam’s lab suggests that conditioned media experiments with RAW264.7 
cell culture supernatant and mature 3T3-L1 adipocytes increased catecholamine secretion 
levels. This study demonstrates, for the first time, XN-induced polarization of 
macrophages toward the anti-inflammatory phenotype beiges WAT as demonstrated by 
enhanced IL-10 secretion, UCP1 expression, and mitochondrial biogenesis within the 
transwell co-culture system, mediating XN’s multi-faceted anti-obesity effects. 
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6.6 Figures 
A.    
B.    
Figure 26. XN-stimulated RAW264.7 cells indirectly beige 3T3-L1 adipocytes. A. 
Direct effects of mature 3T3-L1 adipocytes treated with varying concentrations of XN for 
24 hours. B. Indirect effects of co-culturing of RAW264.7 macrophages and mature 3T3-
L1 adipocytes treated with XN for 24 hours. All data are presented as mean ± SEM. 
Statistical significance between control and treatment groups is represented as *P<0.05, 
** P < 0.01. 
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Figure 27. Mitochondrial content in mature 3T3-L1 adipocytes co-cultured with XN 
stimulated RAW264.7 macrophages. All data are presented as mean ± SEM. Statistical 
significance between control and treatment groups is represented as *P<0.05. 
  
Control   XN 25µM   IL-4 20ng/mL 
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Figure 28. Catecholamine secretion levels in XN treated macrophages co-cultured 
with 3T3-L1 adipocytes. All data are presented as mean ± SEM. Statistical significance 
between control and treatment groups is represented as * P <0.05. 
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Figure 29. Effect of XN treated macrophages co-cultured with 3T3-L1 adipocytes on 
IL-10 secretion levels. All data are presented as mean ± SEM. Statistical significance 
between control and treatment groups is represented as ** P < 0.01, *** P < 0.001. 
 
  
Samuels  82 
 
 
 
 
 
 
Chapter Five  
Conclusions 
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 Provided that obesity is a result of energy imbalance and chronic inflammation, 
WAT stores excess energy in the form of triglycerides. Phytochemicals that increase 
sympathetic nervous system activation to increase thermogenesis, increase brown/beige 
adipocyte proliferation, activate brown adipocytes, polarize macrophages towards the 
anti-inflammatory phenotype, or beige adipocytes, may alleviate adipose tissue 
dysfunction.  
 Research directed toward understanding the responsiveness of activated BAT to 
achieve and maintain energy homeostasis could provide novel anti-obesity therapies. 
Furthermore, targeting adipose tissue-specific inflammation could also supplement 
combating obesity. The present study offers novel insights into the role of the prenylated 
flavonoid XN in inducing the brown fat-like phenotype in 3T3-L1 adipocytes and the 
polarization of macrophages.  
 We have successfully demonstrated that XN induces the beige phenotype in 3T3-
L1 adipocytes and drives thermogenic programming as witnessed by the significant 
elevation of brown/beige-fat specific proteins such as UCP1, CIDE-A, TBX-1, ZIC1, and 
PGC-1α. It has been identified that beige adipocytes, not brown adipocytes, express 
TBX-1 [102]. This led us to the conclusion that XN has a role in inducing the beige 
phenotype. Additionally, XN upregulated the expression of the brown/beige adipocyte 
specific UCP1 protein, confirming the acquired brown-like phenotype in XN-stimulated 
3T3-L1 adipocytes. 
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 Once white adipocytes are transdifferentiated into beige adipocytes, these beige 
adipocytes acquire large amounts of mitochondria [103]. Our data demonstrates that XN 
increased mitochondrial biogenesis, as evidenced by the upregulation of PGC-1α, a 
transcriptional regulator of mitochondrial biogenesis and function, and MitoTracker™ 
green assay. XN also appeared to decrease adipogenesis and promote lipolysis as 
witnessed by a decrease in lipid content and lipid droplet size, therefore reducing 
adiposity. 
 Macrophages are regarded as prominent mediators in obesity. Their sub-
populations, M1 and M2, could have deleterious or protective functions in the 
inflammatory response depending on their microenvironment. Manipulation of the ratio 
of M1/M2 macrophages could have a therapeutic effect in the treatment of obesity. 
 In the present study, we demonstrated that XN possesses immunomodulatory and 
anti-inflammatory activities in RAW264.7 macrophages. XN upregulated the classical 
M2 marker, arginase – 1, in RAW264.7 cells. Additionally, XN induced the secretion of 
catecholamines and IL-10 from RAW264.7 cells, suggesting that monocytes have been 
promoted towards the anti-inflammatory phenotype. XN prevented the polarization of 
monocytes towards the pro-inflammatory phenotype as evidenced by the attenuation of 
IFN-γ-induced iNOS expression and nitrite release.    
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 The activation of AMPK is crucial in maintaining energy homeostasis. Our data 
show that XN significantly upregulates the expression of activated AMPK in both 3T3-
L1 adipocytes and RAW264.7 cells and its effect was abolished by inhibition with 
dorsomorphin of AMPK. Further, using the AMPK activator, AICAR, and inhibitor, 
dorsomorphin, we found that XN-induced beiging of 3T3-L1 adipocytes and anti-
inflammatory polarization of macrophages is mediated through the activation of the 
AMPK signaling pathway.  
 In conclusion, our findings suggest that XN possesses multi-faceted anti-obesity 
effects, making for an attractive pharmacological drug therapy for the treatment and 
prevention of obesity. Our in vitro data provides novel evidence of XN’s role in the 
modulation of improving the metabolic profile. 
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